16 November 2016 - In an unprecedented move, a government panel decided Wednesday to cut the official price of cancer drug Opdivo by 50%, amid fears that widespread use of the newly approved and super-expensive drug could drain state coffers.

The Central Social Insurance Medical Council, better known as Chuikyo and comprised of medical interest group representatives, decided on the emergency price-cutting measure targeting Opdivo, an anti-cancer drug developed by Ono Pharmaceutical Co.

Read Japan Times article